An ongoing trial assessing an oral ATR inhibitor in combination with olaparib for advanced solid tumors (including ATM mutant pancreatic cancer) will be informative (ClinicalTrials.gov Identifier: NCT03682289). This evidence concerns the gene ATR and familial pancreatic carcinoma.